Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SIGA logo SIGA
Upturn stock ratingUpturn stock rating
SIGA logo

SIGA Technologies Inc (SIGA)

Upturn stock ratingUpturn stock rating
$8.58
Last Close (24-hour delay)
Profit since last BUY0.35%
upturn advisory
Consider higher Upturn Star rating
BUY since 6 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: SIGA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit -23.04%
Avg. Invested days 30
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 461.51M USD
Price to earnings Ratio 9.64
1Y Target Price 17.53
Price to earnings Ratio 9.64
1Y Target Price 17.53
Volume (30-day avg) -
Beta 0.95
52 Weeks Range 4.48 - 11.62
Updated Date 06/29/2025
52 Weeks Range 4.48 - 11.62
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.67

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 40.33%
Operating Margin (TTM) -32.03%

Management Effectiveness

Return on Assets (TTM) 14.4%
Return on Equity (TTM) 25.47%

Valuation

Trailing PE 9.64
Forward PE 9.81
Enterprise Value 300868611
Price to Sales(TTM) 3.84
Enterprise Value 300868611
Price to Sales(TTM) 3.84
Enterprise Value to Revenue 2.5
Enterprise Value to EBITDA 5.28
Shares Outstanding 71441104
Shares Floating 40427794
Shares Outstanding 71441104
Shares Floating 40427794
Percent Insiders 43.29
Percent Institutions 51.72

ai summary icon Upturn AI SWOT

SIGA Technologies Inc

stock logo

Company Overview

overview logo History and Background

SIGA Technologies Inc. was founded in 1995. It focuses on developing and commercializing solutions for life-threatening infectious diseases and bioweapons, with a primary focus on smallpox.

business area logo Core Business Areas

  • Pharmaceuticals: Development, production, and commercialization of pharmaceutical products, primarily focused on antiviral drugs.

leadership logo Leadership and Structure

Dr. Phillip L. Gomez is the Chief Executive Officer. The company has a typical corporate structure with departments overseeing R&D, manufacturing, sales, and administration.

Top Products and Market Share

overview logo Key Offerings

  • Tpoxx (Tecovirimat): Tpoxx is an oral antiviral drug for the treatment of human smallpox disease. SIGA is the sole provider of a small molecule drug to treat smallpox, making it a unique offering with a solid market share. No other drugs are currently approved for smallpox treatment. Competitors include companies offering preventative vaccines such as Emergent Biosolutions (EBS).

Market Dynamics

industry overview logo Industry Overview

The industry focuses on biodefense and countermeasures against infectious diseases. Government contracts are a significant driver of revenue.

Positioning

SIGA is a key player in the biodefense market, holding a dominant position with Tpoxx. Competitive advantage lies in its sole-source contract for a small molecule drug for smallpox treatment.

Total Addressable Market (TAM)

The TAM includes government spending on biodefense and stockpiling programs. The global market is projected to be worth over $10 billion. SIGA is well-positioned to capture a significant portion of this market, particularly in the U.S.

Upturn SWOT Analysis

Strengths

  • Sole provider of Tpoxx
  • Strong government relationships
  • Significant government contracts
  • Experienced management team

Weaknesses

  • Reliance on a single product
  • Dependence on government funding
  • Potential for generic competition (though protected by patents)
  • Volatility in government spending

Opportunities

  • Expansion into other antiviral markets
  • Increased government funding for biodefense
  • Partnerships with other pharmaceutical companies
  • Geographic expansion of Tpoxx sales

Threats

  • Changes in government policy
  • Emergence of new infectious diseases
  • Patent challenges
  • Competition from other biodefense companies

Competitors and Market Share

competitor logo Key Competitors

  • EBS
  • CMRX

Competitive Landscape

SIGA holds a dominant position due to Tpoxx. Competitors focus on vaccines and other biodefense solutions. SIGA's advantage is its sole-source drug for smallpox.

Growth Trajectory and Initiatives

Historical Growth: Growth has been driven by government contracts for Tpoxx. The company has seen significant revenue increases in recent years.

Future Projections: Future growth is expected to be driven by continued government stockpiling and potential expansion into new markets and indications.

Recent Initiatives: Recent initiatives include securing new government contracts and exploring potential new applications for Tpoxx.

Summary

SIGA Technologies is a strong company with a unique position in the biodefense market due to its sole-source contract for Tpoxx. Its dependence on government funding is a risk, but continued government support for biodefense programs bodes well. The company should look to expand into other antiviral markets to diversify its revenue stream. Patent challenges and changes in government policy are ongoing threats.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Investor Relations
  • Market Research Reports
  • Analyst Reports

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be made based on your own due diligence and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About SIGA Technologies Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 1997-09-09
CEO & Director Dr. Diem Nguyen M.B.A., Ph.D.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 46
Full time employees 46

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.